Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002649 · ClinicalTrials.gov registry record · Phase 1
Study of Tofacitinib in Refractory Dermatomyositis
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03002649: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT03002649 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03002649, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to obtain preliminary data regarding the safety and efficacy of Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory dermatomyositis.
Interventions
- DRUG Tofacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-01 |
| Est. Completion | 2020-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03002649
The ClinicalTrials.gov registry entry for NCT03002649 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tofacitinib is the first listed.
NCT03002649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03002649 about?
NCT03002649 is a clinical study titled "Study of Tofacitinib in Refractory Dermatomyositis". The purpose of this study is to obtain preliminary data regarding the safety and efficacy of Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory dermatomyositis.
What is the current status of trial NCT03002649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-01. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT03002649?
The interventions under investigation include: Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT03002649?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.